Photo by Prix Galien
By Professor Mahendra G Patel, OBE FRPharmS (pictured second from left)
The PRINCIPLE and PANORAMIC COVID trial teams have been honoured with the Prix Galien, Best Public Sector Innovation Award 2024, the highest accolade in the field of global health research. As the Pharmacy and Inclusion and Diversity Lead for the trials, I’m hugely proud that the award recognises the groundbreaking contributions the teams made in the fight against COVID-19, in pursuit of treatments including repurposed medicines and novel antiviral agents for people most at risk of serious illness, and in particular their commitment to inclusivity and diversity in research.
What were the trials about?
The PRINCIPLE and PANORAMIC trials provided invaluable insights into potential treatments for COVID-19 and set new standards for how clinical trials can be conducted swiftly and efficiently during a global health crisis through innovative research methodologies. Their work helped to shape public health responses and treatment protocols worldwide, making a tangible impact on the fight against the pandemic.
Tackling health inequalities
One of the most significant aspects of the trials was their focus on addressing health inequalities through ensuring research equity, an area of special interest to me. I’m a passionate advocate for health equity, and believe it’s vital that we use inclusive research practices to ensure ethnically and socioeconomically diverse populations and underserved communities are meaningfully represented in clinical trials.
COVID-19 disproportionately affected ethnic minority communities, families living in areas of high deprivation, and people with learning difficulties, exposing deep-seated health inequalities. Working through our exceptional pharmacy network across the UK, along with health and public health professional networks, NHS organisations and importantly religious and community groups, we ensured that these disparities were actively addressed.
The innovative inclusion and diversity strategies focused on recruiting participants from diverse backgrounds, ensuring that the findings from the PRINCIPLE and PANORAMIC trials were representative and applicable to the wider population
The importance of inclusive research
The recognition of the PRINCIPLE and PANORAMIC trials with the Prix Galien serves as a powerful reminder of the importance of inclusive research. Clinical trials that prioritise diversity are better equipped to understand the varied impacts of diseases across different populations and to develop treatments that are effective and safe for all. This includes designing studies that reflect the demographics of the population, actively engaging with minority communities, and addressing barriers to participation in clinical trials.
Committed to health equity
I am confident that the principles embodied by these trials will continue to inspire researchers worldwide. By maintaining a steadfast focus on diversity and inclusion, the global health research community can ensure that the benefits of scientific advancements are shared equitably, paving the way for a healthier and more just world. In my eyes, the award serves as a resolute call to action for the continued pursuit of robust equity in clinical trials, ensuring that everyone, regardless of ethnic, socioeconomic, or other backgrounds, can benefit from the advancements in medical science.
Pharmacist or pharmacy technician? Develop your research skills with our free NIHR e-Learning modules.
Discover funding opportunities in research.
Read more RPS blogs.